Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients

  • 27 Accesses

  • 24 Citations

Abstract

Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary movement, autonomic disturbances and drowsiness, using a rating scale, and their blood pressures and pulse rates were recorded. Blood was collected for plasma fluphenazine and plasma prolactin assay. Additionally, a handwriting test was applied. A higher incidence of unwanted drug effects occurred when plasma fluphenazine concentrations were maximal, but this was not so with prolactin concentrations. No significant blood pressure changes occurred. Small increases in pulse rate and decreases in handwriting length occurred, but these changes were not associated with high fluphenazine levels.

This is a preview of subscription content, log in to check access.

References

  1. Altamura AC, Whelpton R, Curry SH (1979) Animal model for fluphenazine kinetics after administration of long-acting esters. Biopharmaceutics and Drug Disposition 1:65–72

  2. Asberg M, Montgomery S, Perris C, Schalling D, Sedvall G (1978) The Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand 271s:10–27

  3. Curry SH, Altamura AC, Montgomery SA (1979b) Unwanted effects of enanthate and decanoate. Lancet 1:331–332

  4. Curry SH, Whelpton RW, de Schepper PJ, Vranckx S, Schiff AA (1979a) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7:325–331

  5. Kane J, Quitlain F, Rifkin A, Klein DF (1978) Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. Am J Psychiatr 135:1539–1542

  6. Keskiner A, Itil TM, Holden JMC (1969) Fluphenazine enanthate and decanoate: a comparative study in chronic schizophrenic out-patients. Psychosomatics 10:42–45

  7. Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radio-immunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol 8:565–570

  8. Wiles DH, Kolakowska T, McNeilly AS, Mandelbroke BM, Gelder MG (1976) Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug some of its metabolites and prolactin during acute treatment. Psychol Med 6:407–415

Download references

Author information

Correspondence to A. C. Altamura.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Altamura, A.C., Curry, S.H., Montgomery, S. et al. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87, 30–33 (1985). https://doi.org/10.1007/BF00431773

Download citation

Key words

  • Fluphenazine
  • Long-acting esters
  • Side effects
  • Prolactin
  • Double-blind trial
  • Neuroleptics